Thera-SAbDab

ALOMFILIMAB

> Structural Summary

Therapeutic	Alomfilimab
Target	ICOS
Heavy Chain	EVQLVESGGGVVRPGGSLRLSCVASGVTFDDYGMSWVRQAPGKGLEWVSGINWNGGDTDYSDSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCARDFYGSGSYYHVPFDYWGQGILVTVSS
Light Chain	EIVLTQSPGTLSLSPGERATLSCRASQSVSRSYLAWYQQKRGQAPRLLIYGASSRATGIPDRFSGDGSGTDFTLSISRLEPEDFAVYYCHQYDMSPFTFGPGTKVDIK
100% seqID Fv Structure	7joo [Fvs: HL]
99% seqID Fv Structure	None
95-98% seqID Fv Structure	None

100% seqID Structure	7joo [Fvs: HL]

> SAbPred Links

Follow these links to our prediction tools:

Model the variable domain structure with ABodyBuilder
Test for possible therapeutic developability issues with TAP
Assign canonical forms by sequence with SCALOP
Number the sequences in any numbering scheme with ANARCI: [heavy] [light]

Format	Whole mAb
Isotype	G1
Highest Clinical Trial (January '23)	Phase-II
Estimated Status (January '23)	Active
Recorded Developmental Technology	na
INN Year Proposed	2020
INN Year Recommended	None
Companies Involved	Kymab
Conditions Approved	na
Conditions Active	Gastic cancers, Non-small cell lung cancer, Melanoma, Hepatocellular carcinoma, Esophageal cancer, Head and neck squamous cell carcinoma
Conditions Discontinued	na
Notes

SAbDab papers

Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]

Dunbar, J., Krawczyk, K. et al. (2014) SAbDab: the Structural Antibody Database. Nucleic Acids Res. 42(D1):D1140-D1146 [link]

Thera-SAbDab paper

Raybould, M.I.J., Marks, C. et al (2020) Thera-SAbDab: the Therapeutic Structural Antibody Database. Nucleic Acids Res. 48(D1):D383-D388. [link]

Our privacy policy